



We are Daiichi Sankyo.

Every cancer journey is a unique and personal experience for patients and very complex to be fully understood. We know that every cancer patient may also be a mother or father who want to see their children smile. A partner, a friend, a daughter, a son who long to kiss and hug their loved ones. It is with this knowledge that we conduct our science and research to see another warm embrace, another smile or touch – we know how much they matter. A cancer diagnosis should not be the end of these essential moments. That is what we believe in and why we work relentlessly to answer patients' needs in the best possible way.

Our purpose

To contribute to the enrichment of quality of life around the world.

Our mission


To create innovative pharmaceuticals addressing diverse medical needs.

Our vision

To become an innovative global healthcare company contributing to the sustainable development of society.

Our disease areas

With passion for true innovation we seek to transform standards in cancer patient care. All our scientific and research efforts seek to address areas of unmet medical need. By 2025 we want to become a global pharma innovator with competitive advantage in oncology and a trusted partner to the patient communities we serve.



R&D: Research & Development

* as of April 2021


**https://www.daiichisankyo.com/files/investors/library/materials/2021/20210405_5th_MTP_E.pdf

Our strength: science & technology

T-DXd is an ADC composed of 3 components^{1,2}:

- A humanized anti-HER2 IgG1 mAb with the same amino acid sequence as trastuzumab, covalently linked to:
- A topoisomerase I inhibitor payload, an exatecan derivative, via
- A tetrapeptide-based cleavable linker

Humanized anti-HER2 IgG1 mAb^{1,2}



Payload mechanism of action: topoisomerase I inhibitor^{a,1,2}

High potency of payload^{a,1,2}

High drug to antibody ratio ≈ 8 ^{a,1,2}

Payload with short systemic half-life^{a,1,2}

Stable linker-payload^{a,1,2}

Tumor-selective cleavable linker^{a,1,2}


Bystander antitumor effect^{a,1,4}

ADC: Antibody Drug Conjugate
anti-HER2: anti-human epidermal growth factor receptor 2
DXd: a topoisomerase I inhibitor (payload)
IgG1: Immunoglobulin G
mAb: monoclonal antibody
R&D: Research & Development
T-DXd: trastuzumab deruxtecan

^a The clinical relevance of these features is under investigation.
1, Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67(3):173-185.
2, Ogitani Y, et al. Clin Cancer Res. 2016;22(20):5097-5108.
3, Trail PA, et al. Pharmacol Ther. 2018;181:126-142.
4, Ogitani Y, et al. Cancer Sci. 2016;107(7):1039-1046.



We are a global pharmaceutical company with over 120 years of scientific expertise



- 1977**
Launched Krestin (Poly-saccharide-K) in Japan to treat gastrointestinal, lung and breast cancer
- 1985**
Launched the first natural-type interferon beta preparations for brain tumour and skin cancer in Japan
- 1995**
Received approval of irinotecan, the first chemotherapy to demonstrate survival benefits in colorectal cancer

Medicines in our portfolio:

Irinotecan

the first chemotherapy to demonstrate survival benefit in colorectal cancer

Pravastatin

a globally groundbreaking anti-hyperlipidemic agent

Adrenalin

an adrenal cortex hormone that became the first blockbuster medicine of the 20th century

Edoxaban

an anticoagulant and direct factor Xa inhibitor

2012

Launched denosumab in Japan for treatment of bone complications of multiple myeloma and bone metastases of solid tumours.

2020

>20 compounds in development directed at a range of diseases with unmet medical needs, with a focus on ADC technology

2021

In January 2021, ENHERTU® (trastuzumab deruxtecan) received EMA approval for HER2-positive metastatic breast cancer in Europe**

**We have more than 40 years of experience
in bringing cancer therapies to patients**



ONP/21/0049
Date latest revision: 07/21

ADC: Antibody Drug Conjugate
EMA: European Medicines Agency

HER2: Human Epidermal growth factor Receptor 2
R&D: Research & Development

* https://www.daiichisankyo.com/files/investors/library/quarterly_result/2020/pdf/FY2020_Q4_Financial_Results_Presentation_EE.pdf

**Enherthu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens SmPC at www.ema.europa.eu

 **Daiichi-Sankyo**

Passion for Innovation.
Compassion for Patients.™